glp-1 drugs key developments 2025 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Weight Loss Drugs: How
Description
In addition to profoundly compromising quality of life and daily functioning, this disorder contributes to the pathogenesis of numerous chronic diseasesincluding hypertension, coronary artery disease, stroke, diabetes, and cognitive impairmentand has been correlated with elevated all-cause mortality risk (46)
doi: 10.1530/JOE-23-0226
The report also forecasts the Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031
Nevertheless, given the inability to ensure absence of long-term adverse effects for this novel therapy, clinicians should remain vigilant
